Acute myelocytic leukemia.
Acute myelocytic leukemia.
复制标题
急性粒细胞白血病。
DOI：
10.1001/archinte.1976.03630120029012
复制
发表时间：
1976
影响因子：
--
通讯作者：
J. Cuttner
中科院分区：
文献类型：
--
作者：
J. Holland;O. Glidewell;R. Ellison;Robert W. Corey;Joel Schwartz;H. Wallace;H. Hoagland;P. Wiernik;K. Rai;J. Bekesi;J. Cuttner
急性髓细胞白血病（AML）患者和急性淋巴细胞白血病（ALL）患者化疗反应之间的差异似乎更多地是由于正常骨髓组织缺乏再生，而不是肿瘤细胞对化疗缺乏敏感性。与 AML 中的白血病细胞相比，ALL 的淋巴母细胞更容易受到诱导治疗的损伤。然而，使用多种骨髓抑制药物很容易导致 AML 患者出现骨髓再生障碍。治疗困境在于，在这方面有效的治疗也会损害正常的骨髓组织。在因感染或出血而死亡之前的这段时间内，这种损伤通常无法修复。事实上，在骨髓这样的关键器官中，肿瘤细胞和正常细胞之间的分化完全可以在化疗的基础上完成，这一事实是值得注意的。那
The difference between the chemotherapeutic response in patients with acute myelocytic leukemia (AML) and in those with acute lymphocytic leukemia (ALL) would appear to be more a problem of lack of regeneration of normal myeloid tissues than a lack of susceptibility of the neoplastic cell to chemotherapy. The lymphoblasts of ALL are more readily damaged by treatments used in induction than are the leukemic cells in AML. It is easily possible, however, to produce marrow aplasia in patients with AML with the multitude of myelosuppressive drugs available. The therapeutic dilemma is that treatments that are active in this regard also damage the normal myeloid tissue. This damage is often not repaired during the period available prior to death from infection or bleeding. The fact that differentiation between neoplastic and normal cells can be accomplished at all on chemotherapeutic grounds in such a critical organ as the marrow is remarkable. That